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Abstract: 
In this study, chemical feature based pharmacophore models of MMP-1, MMP-8 and MMP-13 inhibitors have been developed with 
the aid of HypoGen module within Catalyst program package. In MMP-1 and MMP-13, all the compounds in the training set 
mapped HBA and RA, while in MMP-8, the training set mapped HBA and HY. These features revealed responsibility for the high 
molecular bioactivity, and this is further used as a three dimensional query to screen the knowledge based designed molecules. 
These pharmacophore models for collagenases picked up some potent and novel inhibitors. Subsequently, docking studies were 
performed for the potent molecules and novel hits were suggested for further studies based on the docking score and active site 
interactions in MMP-1, MMP-8 and MMP-13.  
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Background: 
Variety of biological processes such as embryonic development, 
tissue remodeling and tissue repair involve controlled 
degradation of extra cellular matrix (ECM).  This feature is a 
fundamental part of growth, invasion, and metastasis of 
malignant tumors [1]. Matrix metalloproteinases (MMPs), a 
family of extracellular zinc-dependent neutral endopeptidases, 
are collectively capable of degrading essentially all ECM 
components.  They are the prime factors indulged in breaking 
down the extracellular matrix contributing to disease states 
such as arthritis, atherosclerosis, tumor cell invasion and 
metastasis [2-4]. They are classified according to their domain 
structure into collagenases, gelatinases, stromelysins, matrilysin 
and membrane type MMPs (MT-MMPs) [5].  
 
Among MMPs, collagenases are intimately involved in collagen 
homeostasis by post-translational proteolytic degradation. They 
principally comprise MMP-1 (collagenase-1), MMP-8 
(collagenase-2) and MMP-13 (collagenase-3) [6]. Collagenases 
are the only endogenous enzymes that can readily cleave the 
triple helical domain of fibrillar collagens I, II and III. Collagen 
degradation is commenced by collagenases by making a site-
specific cleavage about three-quarter of the distance from N-
terminus, followed by spontaneous collagen denaturation [7]. 
These interstitial collagenases degrade type I, II and III collagen 
in cartilage; this is a committed step in the development of 
rheumatoid arthritis as well as osteoarthritis and is revealed by 
elevated levels of these collagenases [8, 9].  
 
Collagenases show interesting differences in the crystal 
structures, despite being highly homologous to one another. X-BIOINFORMATION  open access 
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ray analyses of the enzyme–inhibitor complex of collagenases 
suggested that the S1' subunit is a selectivity pocket for 
collagenase inhibitors [10-13]. The S1' subsite, also called the 
S1'-specificity pocket, is the most prominent pocket within the 
catalytic domain of collagenases. Differences in the relative size 
and shape of the S1' pockets in MMP-1, MMP-8 and MMP-13 
suggest that this pocket is a critical determinant of MMP 
inhibitor selectivity [1]. The quite flexible loop forms a major 
portion of the S1' pocket and it undergoes a conformational 
change on inhibitor binding [14, 15]. The loop is of the same 
length in MMP-8 and MMP-13 and two residues are shorter in 
MMP-1[16]. A comparison of the available 3D structure of 
MMP-1, MMP-8 and MMP-13 shows the variability of amino 
acid residues in the S1' loop. This variability of the amino acid 
residues in the S1' loop causes difference in the shape of loops 
[16]. The structural features of these enzymes are most decisive 
in determining MMP substrate specificity and thereby inhibitor 
specificity which is enclosed within the catalytic domain [17]. 
Synthetic inhibitors specifically targeting MMP-1, MMP-8 and 
MMP-13 are unclear. Selectivity is more vital in minimizing the 
detrimental effects during long term medical treatment [18]. It 
has been reported that side effects were observed in the clinical 
studies of collagenase inhibitors, because they showed broad-
spectrum inhibition. Therefore, specific inhibition of MMP-1, 
MMP-8 and MMP-13 are considered to be an attractive target in 
drug discovery research [19, 20]. 
 
In the present study, we have generated pharmacophore 
models using Catalyst [21, 22] software for a diverse set of 
collagenase inhibitors (MMP-1, MMP-8 and MMP-13) with an 
aim to obtain pharmacophore model that would provide the 
chemical features responsible for activity. These 
pharmacophore features were used to screen the databases to 
find novel inhibitors. Further induced fit docking was 
performed to validate these inhibitors against MMP-1, MMP-8 
and MMP-13. This in turn would be able to provide useful 
knowledge for developing specific new and active drug 
candidates targeting collagenases (MMP-1, MMP-8 and MMP-
13).  
 
Methodology: 
Pharmacophore modeling using Catalyst: 
 A set of 337 MMP-1 inhibitors with activity ranging from 0.4 
nM to 100000 nM, 148 MMP-8 inhibitors with activity ranging 
from 0.13 nM to 78000 nM and 371 MMP-13 inhibitors with 
activity ranging from 0.16 nM to 100000 nM were selected from 
GOSTAR (gostardb.com).  The molecules were divided into 
training and test set for the development and validation of 
pharmacophore models. The selection of training set is the most 
crucial part as it determines the quality of generated 
pharmacophore models.  In this study, 21 of 337, 22 of 148 and 
21 of 371 compounds were chosen for training set based on the 
diversity observed in their chemical structures and 
experimental activities for MMP-1, MMP-8 and MMP-13 
respectively. The remaining compounds were used as test set 
for pharmacophore validation process. All the molecules were 
exported and then minimized using modified CHARMM force 
field in catalyst package [21, 22]. For each molecule, a maximum 
of 250 conformations were generated using the 'best quality' 
conformational search option within Catalyst’s ConFirm 
module. It generates the conformations using 'Poling' 
algorithm. The molecules were then submitted to the catalyst 
hypothesis generation.  
 
Model validation and Knowledge based screening  
The best pharmacophore hypothesis was used initially to screen 
316 MMP-1, 126 MMP-8 and 350 MMP-13 test set molecules. 
The same model has also been used to select potent molecules 
from 10,000 library molecules designed using Scaffold Hoping 
(Knowledge based screening). Library molecules were 
generated based on the knowledge of binding interaction of 
known ligands reported with MMP-1, MMP-8 & MMP-13 and 
also the common features necessary for biological activity of 
molecule  [24-26].  These molecules were built using Cerius2 
software  [27] and conformations for each compound were 
generated using best conformational analysis. These molecules 
were further screened for their activities using the developed 
pharmacophore models. 
 
Ligand preparation 
Ligand structures were built using Maestro v9.1 and 
geometrically minimized using OPLS_2005 force field by 
ligprep module of Maestro 9.1 (Schrödinger suite, LLC) [28]. 
Ligprep produces a single, low energy, 3D structure for each 
input structure with various ring conformations, ionization 
states and tautomers using various criteria including molecular 
weight or specified numbers and types of functional groups 
present.  
 
Protein preparation 
Protein preparation and refinement studies were performed on 
MMP-1 (PDB ID: 1HFC), MMP-8 (PDB ID: 3DPE) and MMP-13 
(PDB ID: 1XUC) using protein preparation module 
(Schrödinger suite, LLC) [28] in which the water molecules 
were removed, hydrogen atoms were added, bond orders were 
assigned and orientation of hydroxyl groups were optimized. 
Finally, energy minimization was carried out using default 
constraint of 0.3 Å RMSD and OPLS 2005 force field.  
 
Induced fit docking 
Induced fit docking method for protein structures of MMP-1, 
MMP-8 and MMP-13 was performed using Induced fit docking 
of Schrodinger package [28].  During docking process, the 
ligands were optimized using OPLS or MMFF force field, thus 
changing its conformation to find the best fit that can closely fit 
to the S1' pocket of MMP-1,MMP-8 and MMP-13. The binding 
affinity of each protein and ligand complex was reported as 
Glide Score [29]. All graphic images were picturised using 
PyMol program (www.pymol.org) [30]. Non-bonded 
interactions like hydrophobic was observed using LigPlot 
program  [31] and these interactions can increase the binding 
affinity between target drug interfaces.  
 
Result & Discussion: 
Synthetic inhibitors taken for this study include hydroxamate, 
non-hydroxamate, carboxylate, phosphinate, 
aminocarboxylates, thiol, sulphonates, pyrrolidine, diazepine, 
etc., which tends to have a greater inhibition towards MMPs 
[18]. Hydroxamate diazepine and phenyl sulfonyl acetamide 
inhibitors are potent inhibitors of MMP-9 and MMP-13 both in 
vitro and in vivo, for osteoarthritis in rabbit model [32, 33]. Since 
many of them have been quite potent and in some cases fairly 
selective against collagenases, these molecules were further BIOINFORMATION  open access 
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taken as a basement to design the target specific inhibitors for 
collagenases (MMP-1, MMP-8 and MMP-13) using 
pharmacophore modeling.  
 
 
Figure 1: Structures of some of the training set molecules for (a) MMP-1, (b) MMP-8 & (c) MMP-13 (experimental IC50 values, in 
parentheses). 
 
Figure 2: Hypogen feature with its distance constraints, features are color coded with green: hydrogen bond acceptor, magenta: 
hydrogen bond donor, white: ring aromatic and blue: hydrophobic for MMP-1, MMP-8 and MMP-13. 
 
Pharmacophore generation and validation studies using 
HypoGen 
Ten hypotheses were generated using 21 diverse training set 
molecules for MMP-1 and MMP-13, and 22 molecules for MMP-
8 in HypoGen. (Figure 1 a, b & c) show some of the molecules 
selected as the training set for MMP-1, MMP-8 and MMP-13. 
The best hypothesis for MMP-1 and MMP-13 consists of 1) one 
hydrogen bond acceptor, 2) one hydrogen bond donor and ring 
aromatic whereas MMP-8 consists of 1) two hydrogen bond 
acceptor, 2) one hydrogen bond donor and one hydrophobic. 
The values of ten hypotheses such as cost, correlation (r), and 
root-mean-square deviations (RMSD) are statistically significant 
Table 1A B & 1C (see supplementary material). The 
pharmacophore (Hypo-1, 11 and 21 for MMP-1, MMP-8 and 
MMP-13 respectively) having high correlation coefficient (r), 
lowest total cost, and lower RMSD value was chosen to estimate 
the activity of test set. The best models Hypo-1,11 and 21 for 
MMP-1, MMP-8 and MMP-13 respectively has been given in 
(Figure 2) and the parameters that describe Hypo-1, 11 and 21 BIOINFORMATION  open access 
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for MMP-1, MMP-8 and MMP-13 respectively are shown in 
Table 1A, 1B & 1C (see supplementary material).  
 
 
Figure 3: Shows Hypo-1, 11&21 mapping to highly active and 
low active compounds for MMP-1, MMP-8 & MMP-13 
 
Two statistical methods were employed to rank the ten 
resultant hypotheses. In the first method, all the ten hypotheses 
were evaluated using a test set of known MMP-1, MMP-8 and 
MMP-13 inhibitors, which are not included in the training set. 
Predicted activities of the test set were calculated using all ten 
hypotheses and correlated with the experimental activities. Of 
the ten hypotheses, the best hypothesis Hypo-1 is characterized 
by the highest cost difference (58.88), lowest RMSD value error 
(0.87) and with correlation (0.89) for MMP-1.  Hypo-11 is best 
for MMP-8, with highest cost difference (64.95), lowest RMSD 
value error (1.04) and correlation (0.85). Hypo-21 is the best 
hypothesis for MMP-13 with highest cost difference (63.90), 
lowest RMSD value error (1.15) and correlation (0.87). These 
results conclude that Hypo-1, 11 and 21 are best ranking 
pharmacophore for MMP-1, MMP-8 and MMP-13 respectively, 
among the 10 hypotheses obtained. In MMP-1 and MMP-13, all 
the compounds in the training set  map hydrogen bond 
acceptor (HBA) and ring aromatic (RA),  while in MMP-8, the 
training set map HBA and hydrophobic (HY) and these features 
revealed  that t hey should be  mainly responsible for the high 
molecular bioactivity. Thus this should be taken into account in 
discovering or designing novel inhibitors. The most active 
compounds 1, 22 and 44, has a highest fitness score of 6.80, 8.01 
and 8.20 sequentially, when mapped Hypo-1, 11 and 21 to 
MMP-1, MMP-8 and MMP-13 respectively (Figure 3) whereas 
the least active compounds 21, 43 and 64 maps to a lowest value 
of 4.8, 4.13 and 5.73 (Figure 3). It is evident that as error, weight 
and configuration components are very low and not 
deterministic to the model, the total pharmacophore cost is also 
low and close to the fixed cost. Also, as total cost is less than the 
null cost, this model accounts for all the pharmacophore 
features and has a good predictability power. A second 
statistical test includes calculation of false positives, false 
negatives, enrichment and goodness of hit to determine the 
robustness of hypotheses. Under all validation conditions, 
Hypo-1, 11 and 21 for MMP-1, MMP-8 and MMP-13 
respectively performed superior as compared to the other 
hypotheses and demonstrated excellent prediction of MMP-1, 
MMP-8 and MMP-13 inhibitory activities of the training set 
compounds Table 2A, 2B & 2C (see supplementary material).  
 
Analyzing the results, in MMP-1 out of 7 highly active 
molecules, 5 were predicted correctly as highly active, and the 
rest were predicted as moderately active. Among the 9 
moderately active molecules, 6 molecules were predicted as 
moderately active, 2 were predicted as highly active and 1 was 
predicted as low active molecule. Out of 5 low active molecules, 
one was predicted as moderately active and remaining was 
predicted as low active. In MMP-8 out of 10 highly active 
molecules, 8 were predicted correctly as highly active, and the 
rest were predicted as moderately active. Among the 7 
moderately active molecules, 2 molecules were predicted as 
highly active 4 were predicted as moderately active and 1 was 
predicted as low active molecule.  Out of 5 low active 
molecules, 2 were predicted as moderately active and rest was 
predicted as low active. In MMP-13, out of 8 highly active 
molecules, 6 were predicted correctly as highly active, and the 
rest were predicted as moderately active. Among the 9 
moderately active molecules, all molecules were predicted as 
moderately active. Out of 4 low active molecules, 1 was 
predicted as moderately active and rest was predicted as low 
active.  Activities of the compounds were correctly predicted 
and fit values also confer a good measure of how well the 
pharmacophoric features of Hypo-1, Hypo-11 and Hypo-21 for 
MMP-1, MMP-8 and MMP-13 respectively were mapped onto 
the chemical features of the compounds. The best models 
Hypo-1,11 and 21 for MMP-1, MMP-8 and MMP-13 respectively 
has been given in (Figure 2) and the parameters that describe 
Hypo-1, 11 and 21 for MMP-1, MMP-8 and MMP-13 
respectively are given in Table 1A, 1B & 1C (see 
supplementary material).  Figure 3 shows all the features of 
Hypo-1, 11 and 21 for MMP-1, MMP-8 and MMP-13 
respectively (acceptor, donor, hydrophobic and ring aromatic) 
that were mapped onto the highly active compounds of training 
set (1, 22, and 44) and onto the inactive compound of training 
set 21, 43 and 64 for MMP-1, MMP-8 and MMP-13 respectively. 
The correlation values along with above predictions make the 
pharmacophore suitable to predict molecular properties well. 
Hypo-1, 11 and 21 was used to search the test set of known 
MMP-1, MMP-8 and MMP-13 inhibitors respectively. Database 
mining was performed using the BEST flexible searching 
technique. The  results were analyzed using a set of parameters 
such as hit list (Ht), number of active percent of yields (%Y), 
percent ratio  of actives in the hit list (%A), enrichment factor of BIOINFORMATION  open access 
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2.91, 2.82 and 2.96 (E), false negatives, false positives, and 
goodness of hit score of 0.75, 0.70 and 0.80 (GH) [34]. Hypo-1, 
11 and 21 (for MMP-1, MMP-8 and MMP-13 respectively) 
succeeded in the retrieval of 80% of the active compounds. An 
enrichment factor of 2.91, 2.82, 2.96 and a GH score of 0.75, 0.70, 
0.80 indicates that the quality of the model is acceptable.  
 
 
Figure 4: Some of the newly identified potent lead molecules for 
(a) MMP-1, (b) MMP-8 & (c) MMP-13. 
 
Overall, a strong correlation was observed between the 
predicted Hypo-1, 11, 21 and the experimental activity for 
MMP-1, MMP-8, and MMP-13 inhibitory (IC50) of the training 
and test compounds. However, Hypo-1, 11 and 21 models has a 
greater tendency to show false positives. This could be 
attributed to high structural similarity in the active and inactive 
MMP-1, MMP-8 and MMP-13 inhibitors, resulting in inability to 
discriminate this pattern by pharmacophore models.  We have 
selected Hypo-1, 11 and 21 for MMP-1, MMP-8 and MMP -13 
respectively as a 3D query to search a subset of knowledge 
based designed database of 10,000 compounds to retrieve 
compounds with novel structural scaffolds and desired 
features. The initial screening of Hypo-1, 11 and 21 yielded 3000 
compounds and further cluster analysis of these hits 
corresponded to 220 unique cluster representatives. We further 
extended this study to structure-based design to limit the 
number of false positive hits and to further understand the 
binding of inhibitors to the active site of all three MMPs. 
(Figure 4 a, b & c) shows some of the identified and optimized 
potent lead molecules through virtual library screening for 
MMP-1, MMP-8 and MMP-13.  
 
Docking studies for MMP-1, MMP-8 and MMP-13 
For furhter validation, docking is performed for 220 hits (MMP-
1, MMP-8 & MMP-13) using Induced fit docking mode of 
Maestro. Most of the compounds show hydrogen bonding 
interactions with the S1 pocket residues. Docking results shows 
that known (yellow green) and newly identified compounds 
(purple) occupy the S1' loop region with the almost similar 
conformations. Especially, highly active compounds are 
forming at least two specific or unique hydrogen bond 
interactions in the S1' loop and shows high glide score with 
collagenases (MMP-1, MMP-8 and MMP-13). The docking 
scores and the hydrogen bonding interaction for newly 
identified molecules with MMP-1, MMP-8 and MMP-13 were 
shown in Table 3 (see supplementary material). To investigate 
the ligand binding affinity at the hydrophobic S1' pocket, we 
further estimated the hydrophobic interactions using LIGPLOT 
software  (Figure 5). The hydrogen and hydrophobic 
interactions of highly active ligands for MMP-1, MMP-8 and 
MMP-13 are discussed below.  
 
 
Figure 5: Shows docked conformations of molecule 66, 69 & 72 
in the S1 loop of MMP-1, MMP-8 & MMP-13 respectively. 
Dotted lines represent hydrogen bonds.  Hydrophobic 
interactions are represented as arcs. Ligand represented as ball 
and sticks. 
 
Binding mode of molecule - 66 into the S1' loop of MMP-1 
Docking results shows that both the ligands occupy the S1' loop 
region with the almost similar conformation with a glide score -
7.816 and -7.089 Kcal/mol. LigPlot software was used to 
understand the in-depth interaction pattern between both the 
ligands and MMP-1. Hydrophobic interaction was identified 
with amino acid residues Leu 140, Phe 207, Arg 214, Ile 232, Gly 
233, Leu 235, Tyr 237, Ser 239, Tyr 240, Phe 242, Ser 243, Asp 245 
and Gln 247. Both the ligands form hydrogen bonding 
interaction with the Val 246 and specific amino acid residue 
Asp 245 in the S1' loop region of MMP-1 (Figure 5). 
 
Binding mode of molecule - 69 into the S1' loop of MMP-8 
Docking results shows that both the ligands occupy the S1' loop 
region with the almost similar conformation with a glide score -
7.240 and -7.216 Kcal/mol. For the above two ligands   
hydrophobic interaction was seen with amino acid residues Leu 
160, Leu193, Val 194, His 197, Glu 198, Ala 213, Leu 214, Pro 
217, Asn 218, Tyr 219, Ala 220, Arg 222, Thr 224 and Ser 228 
using LigPlot software. Phenyl group in both the ligands BIOINFORMATION  open access 
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occupy the solvent exposed region including His 207, Ser 228 
and Thr 224. Both the ligands form hydrogen bonding 
interaction with the Pro 217 which is unique among MMP-8 and 
also form pi-pi stacking with the Arg 222 in the S1' loop region 
of MMP-8 (Figure 5). 
 
Binding mode of molecule -72 into the S1' loop of MMP-13 
Docking results shows that both the ligands occupy the S1' loop 
region with the almost similar conformation with a glide score -
10.892  and -9.203 Kcal/mol. Using LigPlot software, 
hydrophobic interaction was seen with amino acid residues Leu 
185, Leu 218, Val 219, His 222, Leu 239, Phe 241, Pro 242, Ile 243, 
Thr 245, Tyr 246, Thr 247, Lys 249, Ser 250, His 251, Phe 252 and 
Met 253. Both the ligands form hydrogen bonding interaction 
with the specific amino residue with the Met 253. Molecule 72 
additional ly forms interaction with the Thr 247 and Pro 242 
and also forms pi-pi stacking with the Tyr 244 in the S1' loop 
region of MMP-13 (Figure 5).   
 
Conclusion:  
Statistically validated pharmacophore models were generated 
for collagenase inhibitors to locate the spatial arrangement of 
features, which are necessary for biological activity.  Out of 
them, Hypo-1, 11 and 21 performed superior for MMP-1, MMP-
8 and MMP-13 respectively and also showed excellent 
prediction for inhibitory activities of the test set compounds 
and well complemented with receptor active sites, compared to 
the other hypotheses. The best hypothesis for MMP-1 and 
MMP-13 consists of one hydrogen bond acceptor, one hydrogen 
bond donor and ring aromatic, whereas MMP-8 consists of two 
hydrogen bond acceptors, one hydrogen bond donor and one 
hydrophobic group. These pharmacophore models were used 
to retrieve the molecules from the databases which were further 
validated using docking studies. Finally, three structurally 
diverse compounds with high Glide scores and interactions 
with critical active site amino acids for MMP-1, MMP-8 and 
MMP-13 were identified. From this study, we suggest that these 
molecules can be used for further studies and also serve as 
potential leads against collagenase infections.  
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Supplementary material:  
 
Table 1A: 10 pharmacophore models generated by the Hypogen algorithm for MMP-1  
Hypo No  Total Cost  Cost differencea  Error Cost  RMS deviation  Training set (r)  Featuresb 
1  97.01 58.88  78.68 0.87  0.89  ADR 
2  97.64 58.25  78.30 0.85  0.88  AAD 
3  97.79 58.10  79.25 0.90  0.87  AAD 
4  98.21 57.68  79.88 0.93  0.86  AAD 
5  98.48 57.41  80.79 0.98  0.84  ADR 
6  98.71 57.18  80.07 0.94  0.86  AAD 
7  98.74 57.15  81.20 1.00  0.83  AAD 
8  98.74 57.15  80.22 0.95  0.86  AAD 
9  98.91 56.98  80.28 0.95  0.86  AAD 
10  98.93 56.96  81.23 1.00  0.83  AAD 
a (Null cost-Total cost), Null cost  = 155.89, Fixed cost = 88.07, For the Hypo-1 Weight=2.02 Config=16.31. All cost units are in bits.  
b A- Hydrogen Bond Acceptor, D – Hydrogen Bond Donor, H – Hydrophobic. R- Ring aromatic. 
 
Table 1B: 10 pharmacophore models generated by the Hypogen algorithm for MMP-8  
Hypo No  Total Cost  Cost differencea  Error Cost  RMS deviation  Training set (r)  Featuresb 
11 105.21  64.95  86.02  1.04  0.85  AADH 
12 106.24  63.92  87.05  1.08  0.84  AADH 
13 106.93  63.23  87.76  1.11  0.83  AADH 
14 107.55  62.61  88.02  1.12  0.83  AADH 
15 107.92  62.24  88.60  1.15  0.82  AAAH 
16 108.06  62.10  87.88  1.12  0.82  AADH 
17 108.72  61.44  89.55  1.18  0.81  AADH 
18 108.90  61.26  89.09  1.17  0.82  AAAH 
19 108.98  61.18  89.56  1.18  0.81  AADH 
20 109.02  61.14  89.13  1.17  0.82  AADH 
a (Null cost-Total cost), Null cost = 170.16, Fixed cost = 93.16, For the Hypo-11 Weight=1.14 Config=16.038. All cost units are in bits.  
b A- Hydrogen Bond Acceptor, D – Hydrogen Bond Donor, H – Hydrophobic. R- Ring aromatic 
 
Table 1C: 10 pharmacophore models generated by the Hypogen algorithm for MMP-13  
 
 
 
 
 
 
 
 
 
 
 
 
a (Null cost-Total cost), Null cost  = 168.34, Fixed cost = 88.22, For the Hypo-21 Weight=1.95, Config=16.46. All cost units are in bits.  
b A- Hydrogen Bond Acceptor, D – Hydrogen Bond Donor, H – Hydrophobic. R- Ring aromatic 
 
Table 2A: Experimental and predicted IC50 data of 21 training set molecules for MMP-1 
Molecule Fit  Experimental  Predicted  Errora Experimental  Predicted 
 Value  b IC50. nM  IC50. nM    Scalec Scalec 
1 6.80  10  59 5.9  +++  +++ 
2 6.88  15  49 3.2  +++  +++ 
3 6.53  25  110  4.4  +++  ++ 
4 6.80  34  59 1.7  +++  +++ 
5 6.56  70  100  1.4  +++  +++ 
6 6.54  82  110  1.3  +++  ++ 
7 6.71  96  72 -1.3  +++  +++ 
8 5.93  140  430  3.2  ++  ++ 
9 6.18  170  240  1.4  ++  ++ 
10 6.59  190  94  -2  ++  +++ 
11 6.31  220  180 -1.2  ++  ++ 
12 6.15  300  260 -1.2  ++  ++ 
13 6.82  520  850 3.2  ++  +++ 
14 5.58  750  970 1.3  ++  ++ 
15 5.33  840  1700  2.1  ++  + 
16 6.30  920  190 -4.9  ++  ++ 
17 5.70  1300  730 -1.8  +  ++ 
18 5.51  3000  1100  -2.6  +  + 
19 4.76  8000  6500  -1.2  +  + 
20 4.80  10000  5900  -1.7  +  + 
21 4.80  11000  5900  -1.9  +  + 
 
 
 
 
Hypo No  Total Cost  Cost differencea  Error Cost  RMS deviation  Training set (r)  Featuresb 
21 104.44  63.90  84.72  1.15  0.87  ADR 
22 105.03  63.31  83.72  1.11  0.84  ADR 
23 106.49  61.85  86.24  1.21  0.83  AAR 
24 106.63  61.71  87.21  1.25  0.81  ADR 
25 106.70  61.64  86.87  1.24  0.82  ADR 
26 108.09  60.25  89.38  1.33  0.78  ADR 
27 108.55  59.79  89.51  1.34  0.78  AAR 
28 108.95  59.39  89.13  1.32  0.79  ADR 
29 108.97  59.37  89.32  1.33  0.79  ADR 
30 108.99  59.35  89.33  1.33  0.79  ADR BIOINFORMATION  open access 
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Table 2B: Experimental and predicted IC50 data of 22 training set molecules for MMP-8 
Molecule Fit  Experimental  Predicted  Errora Experimental  Predicted 
 Value  b IC50. nM  IC50. nM    Scalec Scalec 
22 8.01  0.54  0.37  -1.5  +++  +++ 
23 5.88  4.4  50  11  +++  +++ 
24 5.80  10  59  5.9  +++  +++ 
25 5.90  18  47  2.6  +++  +++ 
26 5.80  31  60  1.9  +++  +++ 
27 5.67  50  80  1.6  +++  +++ 
28 5.47  60  130 2.1  +++  ++ 
29 5.93  75  44  -1.7  +++  +++ 
30 5.18  85  250 2.9  +++  ++ 
31 5.69  100  76  -1.3  +++  +++ 
32 5.82  130  57  -2.3  ++  +++ 
33 5.44  180  140 -1.3  ++  ++ 
34 5.05  230  340 1.5  ++  ++ 
35 5.09  300  310 1  ++  ++ 
36 5.57  590  100 -5.8  ++  +++ 
37 4.13  750  2800  3.7  ++  + 
38 5.79  1000  61  -16  ++  +++ 
39 4.72  1100  720 -1.5  +  ++ 
40 4.56  1700  1000  -1.6  +  + 
41 4.15  2500  2700  1.1  +  + 
42 4.63  3000  880 -3.4  +  ++ 
 
Table 2C: Experimental and predicted IC50 data of 21 training set molecules for MMP-13 
Molecule Fit  Experimental  Predicted  Errora Experimental  Predicted 
 Value  b IC50. nM  IC50. nM    Scalec Scalec 
44 8.20  0.1  0.89  8.9  +++  +++ 
45 7.33  5  6.5  1.3  +++  +++ 
46 6.72  15  27  1.8  +++  +++ 
47 6.59  35  36  1  +++  +++ 
48 6.20  45  89  2  +++  +++ 
49 5.61  63  340 5.4  +++  ++ 
50 5.62  72  330 4.6  +++  ++ 
51 6.42  84  53  -1.6  +++  +++ 
52 5.63  130  330 2.5  ++  ++ 
53 5.58  150  370 2.5  ++  ++ 
54 6.06  160  120 -1.3  ++  ++ 
55 5.61  190  340 1.8  ++  ++ 
56 5.64  220  320 1.5  ++  ++ 
57 5.57  310  380 1.2  ++  ++ 
58 5.62  400  330 -1.2  ++  ++ 
59 5.62  520  340 -1.5  ++  ++ 
60 5.63  750  330 -2.3  ++  ++ 
61 5.61  1600  800 -2.6  +  ++ 
62 5.38  2000  1580  -3.4  +  + 
63 5.58  3100  1370  -2.2  +  + 
64 5.73  5200  1260  -2.4  +  + 
a  + indicates that the predicted IC50 is higher than the experimental IC50; − indicates that the predicted IC50 is lower than the experimental IC50; a value of 1 indicates that 
the predicted IC50 is equal to the experimental IC50; b Fit value indicates how well the features in the pharmacophore overlap with the chemical features in the molecule. 
Fit = weight × [max (0.1−SSE)] where SSE = (D/T) 2,; D = displacement of the feature from the center of the location constraint and T = the radius of the location 
constraint sphere for the feature (tolerance). c Activity Scale – IC50 < 100 nM  = +++ (highly active); IC50 =100 – 1000 nM = ++ (moderately active );  IC50 > 1000 nM  =  + 
(low active ). 
 
Table 3: Induced fit score and Hydrogen-bond distance parameter for the molecules 66, 69 and 72 on binding with MMP-1, MMP-8 and MMP-13.  
                                  Hydrogen Bond  S. no  Compound  Induced Fit Score 
Donor Acceptor  Distance  (Ǻ) 
1. 66  -7.816  N-H  C=O  (ASP  245)  1.8 
      N-H  C=O (VAL 246)  2.4 
          
2. 69  -7.240  N-H  C=O  (ARG  222)  1.8 
      N-H  C=O  (PRO 217)  2.3 
          
3.  72  -10.892  O-H  C=O (MET 253)  1.8 
      N-H (THR 247)  S=O  2.3 
      N-H  C=O (PRO 242)  2.4 
 